{"id":869019,"date":"2025-07-14T05:03:14","date_gmt":"2025-07-14T09:03:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/"},"modified":"2025-07-14T05:03:14","modified_gmt":"2025-07-14T09:03:14","slug":"rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/","title":{"rendered":"Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1\/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery\u00a0"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN JOSE, Calif., July  14, 2025  (GLOBE NEWSWIRE) &#8212; Rani Therapeutics Holdings, Inc. (\u201cRani Therapeutics\u201d or \u201cRani\u201d) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill\u00ae capsule at the Endocrine Society\u2019s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA.<\/p>\n<p align=\"justify\">Details of the presentations are as follows:<\/p>\n<p align=\"justify\">\n        <strong>Abstract Title:<\/strong> Oral Delivery of a Bispecific GLP-1\/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines<\/p>\n<p align=\"justify\">\n        <strong>Session Type:<\/strong> Poster Presentation<\/p>\n<p align=\"justify\">\n        <strong>Session Title:<\/strong> Adipose Tissue, Appetite, and Obesity: From Breakthroughs to Real-World Challenges: Navigating Weight Loss, Regain, and Therapeutic Advances II<\/p>\n<p align=\"justify\">\n        <strong>Session Date &amp; Time:<\/strong> July 14, 2025 from 12:00 PM to 1:30 PM PT<\/p>\n<p align=\"justify\">\n        <strong>Poster Number:<\/strong> MON-691<\/p>\n<p align=\"justify\">\n        <strong>Presenting Author:<\/strong> Anvesh Dasari, PhD<\/p>\n<p align=\"justify\">The abstract presented at ENDO 2025 is available on the Endocrine Society\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EejKu_2e8QjNfoD7gkR5JL8TeF61NgcFrUxKxz8mdWbfnyWpe7Em_fG0VB0ElcAsokXwJ1jNSfqlBfny6ytCKgYkCvEPmcPvIoPhMsH3fx7SzYqjGuOUBL37xchmrIPP\" rel=\"nofollow\" target=\"_blank\">website<\/a>.\u00a0<\/p>\n<p align=\"justify\">\n        <strong>About Rani Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill\u00ae capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill\u00ae capsule technology. For more information, visit ranitherapeutics.com.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T0tEpiYEp1io5ikJt__iaZ8MGrhCFfh6SEzE4-bjS6n2triuLt2jXS35_EYCpHJGvGSgG2dKgH-clURuxVl9AujGLG7kfw4dXpvQwTxJI10R21GE-YQt0RN4W-slCrc7\" rel=\"nofollow\" target=\"_blank\">investors@ranitherapeutics.com<\/a>\u00a0\u00a0<\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RbmOPBLC0PTn-NWYnkUbXv7rD8uBHHloM0JaHRGuxwGdtVn1BTpjemiT_IaEn6YPJlaisdJ9EHkqdGrHvTipzz4o6yDrhKR4AUx0M5hu3-9lgeCK9nIqL8etBV87iJYI\" rel=\"nofollow\" target=\"_blank\">media@ranitherapeutics.com<\/a>\u00a0<\/p>\n<p align=\"justify\">\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MzY4MCM3MDQ1Nzc3IzIyMDg2OTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTRjNDQ4ODMtMmU0Zi00NmI3LWIzM2EtZTliZmE5YmUyOTMwLTEyMjAyNTItMjAyNS0wNy0xNC1lbg==\/tiny\/Rani-Therapeutics-LLC.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) &#8212; Rani Therapeutics Holdings, Inc. (\u201cRani Therapeutics\u201d or \u201cRani\u201d) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill\u00ae capsule at the Endocrine Society\u2019s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA. Details of the presentations are as follows: Abstract Title: Oral Delivery of a Bispecific GLP-1\/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines Session Type: Poster Presentation Session Title: Adipose Tissue, Appetite, and Obesity: From Breakthroughs to Real-World Challenges: Navigating Weight Loss, Regain, and Therapeutic Advances II Session Date &amp; Time: July 14, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1\/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery\u00a0&#8220;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-869019","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1\/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery\u00a0 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1\/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery\u00a0 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) &#8212; Rani Therapeutics Holdings, Inc. (\u201cRani Therapeutics\u201d or \u201cRani\u201d) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill\u00ae capsule at the Endocrine Society\u2019s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA. Details of the presentations are as follows: Abstract Title: Oral Delivery of a Bispecific GLP-1\/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines Session Type: Poster Presentation Session Title: Adipose Tissue, Appetite, and Obesity: From Breakthroughs to Real-World Challenges: Navigating Weight Loss, Regain, and Therapeutic Advances II Session Date &amp; Time: July 14, &hellip; Continue reading &quot;Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1\/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery\u00a0&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-14T09:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MzY4MCM3MDQ1Nzc3IzIyMDg2OTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1\\\/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery\u00a0\",\"datePublished\":\"2025-07-14T09:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\\\/\"},\"wordCount\":259,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MzY4MCM3MDQ1Nzc3IzIyMDg2OTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\\\/\",\"name\":\"Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1\\\/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery\u00a0 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MzY4MCM3MDQ1Nzc3IzIyMDg2OTk=\",\"datePublished\":\"2025-07-14T09:03:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MzY4MCM3MDQ1Nzc3IzIyMDg2OTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MzY4MCM3MDQ1Nzc3IzIyMDg2OTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1\\\/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1\/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery\u00a0 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/","og_locale":"en_US","og_type":"article","og_title":"Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1\/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery\u00a0 - Market Newsdesk","og_description":"SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) &#8212; Rani Therapeutics Holdings, Inc. (\u201cRani Therapeutics\u201d or \u201cRani\u201d) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill\u00ae capsule at the Endocrine Society\u2019s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA. Details of the presentations are as follows: Abstract Title: Oral Delivery of a Bispecific GLP-1\/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines Session Type: Poster Presentation Session Title: Adipose Tissue, Appetite, and Obesity: From Breakthroughs to Real-World Challenges: Navigating Weight Loss, Regain, and Therapeutic Advances II Session Date &amp; Time: July 14, &hellip; Continue reading \"Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1\/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery\u00a0\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-14T09:03:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MzY4MCM3MDQ1Nzc3IzIyMDg2OTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1\/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery\u00a0","datePublished":"2025-07-14T09:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/"},"wordCount":259,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MzY4MCM3MDQ1Nzc3IzIyMDg2OTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/","name":"Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1\/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery\u00a0 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MzY4MCM3MDQ1Nzc3IzIyMDg2OTk=","datePublished":"2025-07-14T09:03:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MzY4MCM3MDQ1Nzc3IzIyMDg2OTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MzY4MCM3MDQ1Nzc3IzIyMDg2OTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-and-progen-announce-late-breaking-presentation-at-endo-2025-demonstrating-bioequivalence-of-novel-bispecific-glp-1-glp-2-receptor-agonist-delivered-orally-via-ranipill-compared-to-s\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1\/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/869019","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=869019"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/869019\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=869019"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=869019"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=869019"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}